Express Pharma
Home  »  Latest Updates  »  Strides Shasun posts Q4 FY18 and FY18 results

Strides Shasun posts Q4 FY18 and FY18 results

Read Article

Revenues were at 6,775 million in Q4 FY18

Strides Shasun has announced its Q4 FY18 and FY18 results. In Q4 FY18, revenues were at 6,775 million, EBITDA at 1,005 million. In FY18, revenues were at 28,576 million and EBITDA at 4,369 million. The board recommended a dividend of 2 per share.

Arun Kumar, Group CEO and Managing Director, Strides Shasun, said, “The financial year 2017-18 was a difficult year for Strides. While we continue to build momentum with our strategy, our execution was far from satisfactory. We completed several of our corporate actions including exiting non-core operations and markets that did not add value to our overall goal of being a diversified B2C player globally.”

“In 2018-19 our clear focus will be on the improving the quality of growth which will deliver a strong bounce back in the second half of FY 19.”

Comments are closed.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?